Condition
CFTR Gene Mutation
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06747858Phase 2Recruiting
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT05100823Not ApplicableTerminated
Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies
NCT05818319Not ApplicableRecruiting
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy
Showing all 3 trials